Replies to post #218532 on Biotech Values

[biocqr]

DCPH > $172M raise at 3.7% discount...

Deciphera Pharmaceuticals Announces Pricing of Public Offering

Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the pricing of an underwritten public offering of 4,300,000 shares of its common stock at a public offering price of $40.00 per share for aggregate gross proceeds of $172 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock are being offered by Deciphera. In addition, Deciphera granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock. The offering is expected to close on June 11, 2018, subject to customary closing conditions.

J.P. Morgan and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Canaccord Genuity LLC and JMP Securities LLC are acting as lead managers, and Nomura Securities International, Inc. and Raymond James & Associates, Inc. are acting as co-managers for the offering.

[mcbio]

DCPH - censored patients in P1 trial

Peter, the latest DCPH presentation gives a bit more detail on the prior P1 data in GIST. See slide 19 as it references a number of censored patients: https://investors.deciphera.com/static-files/49c2191e-b58d-4843-b221-1b8061f155a0 . Is there any chance there is any concern with their presented data to date in light of the censored patients? I normally see "censoring" brought up in a negative context so not sure if a red flag here.